2N Pharma
2N Pharma is an innovative biotech company dedicated to developing treatments for neurodegenerative diseases, with a focus on ALS, Parkinson's disease, and frontotemporal dementia. They utilize a groundbreaking approach targeting mitochondrial dysfunction and lipid metabolism, supported by extensive research and collaborations. Their mission is to find effective cures for these incurable conditions through novel small molecule therapeutics, with ongoing clinical and preclinical development, and active engagement in scientific research, funding, and industry events.
Industries
Nr. of Employees
small (1-50)
Products
Mitometin
An orally administered, reversible small-molecule inhibitor of carnitine palmitoyl-transferase 1 (CPT1) developed to modulate lipid β-oxidation and restore metabolic homeostasis in neurodegenerative disease models.
Mitometin
An orally administered, reversible small-molecule inhibitor of carnitine palmitoyl-transferase 1 (CPT1) developed to modulate lipid β-oxidation and restore metabolic homeostasis in neurodegenerative disease models.
Services
Collaborative preclinical research partnerships
Joint research activities with academic groups and external partners to perform preclinical efficacy testing, behavioral analysis and translational biomarker studies.
Collaborative preclinical research partnerships
Joint research activities with academic groups and external partners to perform preclinical efficacy testing, behavioral analysis and translational biomarker studies.
Expertise Areas
- Neurodegenerative drug discovery
- Preclinical animal models and in vivo pharmacology
- Biomarker discovery and translational research
- Medicinal chemistry and small-molecule optimization
Key Technologies
- CPT1 inhibition and modulation of fatty acid β-oxidation
- Small-molecule medicinal chemistry
- Blood–brain barrier penetration assessment
- Rodent disease models (e.g., SOD1 G93A, EAE, Parkinson’s models)